Method of treating or preventing fibromyalgia and other somatoform disorders with a highly selective norepinephrine reuptake inhibitor
US6610690B2 · kind B2 · utility
20Cited by
13References
39Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2002 |
| Grant date | Aug 26, 2003 |
| Priority date | — |
| Expiry date | Jan 25, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.